BioCentury | Feb 26, 2001
Clinical News

Phosphosesquiterpene compounds that inhibit farnesyl transferase regulatory update

...U.S. patent covering methods of inhibiting farnesyl transferase activity with phosphosesquiterpene compounds to treat cancer. NuOncology Labs Inc....
BioCentury | Jul 31, 2000
Clinical News

Derivatives of Arglabin farnesyl transferase inhibitor regulatory update

...covering its dmae-Arglabin, bae-Arglabin and mae-Arglabin phosphosesquiterpene compounds and their use to treat various cancers. NuOncology Labs Inc....
BioCentury | May 1, 2000
Clinical News

Arglabin farnesyl transferase inhibitor regulatory update

...Arglabin compound that is approved in Kazakstan and in U.S. preclinical testing to treat cancer. NuOncology Labs Inc....
BioCentury | Mar 13, 2000
Clinical News

Chlorohydrin-Arglabin regulatory update

...chlorohydrin derivative of the company's Arglabin plant-derived inhibitor of farnesyl transferase to treat various cancers. NuOncology Labs Inc....
BioCentury | Jan 17, 2000
Company News

NuOncology scientific advisory board update

NuOncology Labs Inc. (NLAB), Virginia Beach, Va. Business: Cancer Appointed: Robert Newman, professor of medicine and pharmacology at the University of Texas M.D. Anderson Cancer Center WIR Staff...
BioCentury | Nov 15, 1999
Clinical News

Phosphosesquiterpene compounds regulatory update

...U.S. patent covering the use of phosphosesquiterpene compounds and other compositions to treat various cancers. NuOncology Labs Inc....
BioCentury | Nov 8, 1999
Clinical News

Arglabin farnesyl transferase inhibitor regulatory update

...U.S. patent covering compounds and methods to suppress tumor growth, including novel forms of Arglabin. NuOncology Labs Inc....
BioCentury | Sep 27, 1999
Clinical News

Derivatives of Arglabin inhibitor of farnesyl transferase regulatory update

...allowance for a U.S. patent covering the use of three Arglabin derivatives to treat cancer. NuOncology Labs Inc....
BioCentury | Aug 30, 1999
Clinical News

Arglabin inhibitor of farnesyl transferase regulatory update

...of allowance for a U.S. patent covering the use of NLAB's Arglabin to treat cancer. NuOncology Labs Inc....
BioCentury | Jul 6, 1999
Clinical News

NuOncology regulatory update

...Benzylamino-Arglabin and Morpholine-amino-Arglabin, and methods for using the compounds to suppress tumor growth in humans. NuOncology Labs Inc....
Items per page:
1 - 10 of 13
BioCentury | Feb 26, 2001
Clinical News

Phosphosesquiterpene compounds that inhibit farnesyl transferase regulatory update

...U.S. patent covering methods of inhibiting farnesyl transferase activity with phosphosesquiterpene compounds to treat cancer. NuOncology Labs Inc....
BioCentury | Jul 31, 2000
Clinical News

Derivatives of Arglabin farnesyl transferase inhibitor regulatory update

...covering its dmae-Arglabin, bae-Arglabin and mae-Arglabin phosphosesquiterpene compounds and their use to treat various cancers. NuOncology Labs Inc....
BioCentury | May 1, 2000
Clinical News

Arglabin farnesyl transferase inhibitor regulatory update

...Arglabin compound that is approved in Kazakstan and in U.S. preclinical testing to treat cancer. NuOncology Labs Inc....
BioCentury | Mar 13, 2000
Clinical News

Chlorohydrin-Arglabin regulatory update

...chlorohydrin derivative of the company's Arglabin plant-derived inhibitor of farnesyl transferase to treat various cancers. NuOncology Labs Inc....
BioCentury | Jan 17, 2000
Company News

NuOncology scientific advisory board update

NuOncology Labs Inc. (NLAB), Virginia Beach, Va. Business: Cancer Appointed: Robert Newman, professor of medicine and pharmacology at the University of Texas M.D. Anderson Cancer Center WIR Staff...
BioCentury | Nov 15, 1999
Clinical News

Phosphosesquiterpene compounds regulatory update

...U.S. patent covering the use of phosphosesquiterpene compounds and other compositions to treat various cancers. NuOncology Labs Inc....
BioCentury | Nov 8, 1999
Clinical News

Arglabin farnesyl transferase inhibitor regulatory update

...U.S. patent covering compounds and methods to suppress tumor growth, including novel forms of Arglabin. NuOncology Labs Inc....
BioCentury | Sep 27, 1999
Clinical News

Derivatives of Arglabin inhibitor of farnesyl transferase regulatory update

...allowance for a U.S. patent covering the use of three Arglabin derivatives to treat cancer. NuOncology Labs Inc....
BioCentury | Aug 30, 1999
Clinical News

Arglabin inhibitor of farnesyl transferase regulatory update

...of allowance for a U.S. patent covering the use of NLAB's Arglabin to treat cancer. NuOncology Labs Inc....
BioCentury | Jul 6, 1999
Clinical News

NuOncology regulatory update

...Benzylamino-Arglabin and Morpholine-amino-Arglabin, and methods for using the compounds to suppress tumor growth in humans. NuOncology Labs Inc....
Items per page:
1 - 10 of 13